Legislative Measures in the United States and Europe
====================================================

Recent legislative measures enacted in the United States and Europe are expanding the knowledge of drug use in infants and children by providing important incentives for conducting pediatric studies (**[Table 1](#tbl1){ref-type="table"}**) ([@bib1]). Although the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) updated more than 500 drug labels, only 12 involved anesthetic agents and none were studied in premature infants ([@bib2]). The FDA Safety and Innovation Act (FDASIA, 2012) requires that the FDA obtain additional expertise in Neonatology to assist with all aspects of neonatal drug development, especially complex issues surrounding study design and outcome measures. In addition, FDASIA requires that written requests generated by the FDA under BPCA specifically include neonates. This approach discourages issuing waivers to companies reluctant to conduct studies in neonates due to concerns about safety or limited efficacy unless extremely compelling evidence exists (25% of previous waivers were found after internal audits to have been issued in error) ([@bib3]). Under PREA, pediatric study plans for qualifying drugs must now be submitted following the completion of phase II trials in adults after preliminary safety and efficacy data have been generated ([@bib4]). Pediatric Regulations established in the European Union in 2007 had similar objectives to improve the health of children by facilitating the development and availability of medicines for children ([@bib5]). Enhanced communication between the two regulatory agencies with respect to pediatric drug development now ensures that protocols being conducted in the United States and in Europe will be complementary in design given the more global scope of most pediatric product development.

Why have so Few Studies Been Conducted in Newborn Infants (Especially Preterm Infants)?
=======================================================================================

Over 500,000 premature infants are born annually in the United States and many require admission to a neonatal intensive care unit (NICU), costing \>\$26 billion per year ([@bib6]). Premature infants are at substantial risk of dying or developing serious morbidity that can affect them for life. Although considerable reductions in mortality and morbidity for premature infants occurred after the introduction of antenatal corticosteroids and surfactant 15--20 y ago, significant improvements in outcome have not continued ([@bib7],[@bib8]). This highlights the challenges facing premature infants and indicates that novel approaches to significantly improve outcomes are urgently needed.

In this setting, most medications routinely used in the NICU lack convincing data to support their safety and efficacy and few new medications have been developed over the past two decades to substantially improve outcome. This is especially true for anesthetic agents used for surgical procedures in premature infants ([@bib9]). There are actually significant disincentives to conducting research of anesthetic agents in preterm infants. Many Institutional Review Boards and the FDA are risk averse with this vulnerable population, with some even believing that it is unethical to conduct research in newborns ([@bib10],[@bib11]). Even studies conducted to better define standard of care (e.g., SUPPORT) have been challenged since many regulators are unsure how these types of studies should be conducted ([@bib12],[@bib13],[@bib14]). Premature infants also represent a small market and may develop long-term disabilities which can be associated with significant liability, whether the adverse outcome is caused by the drug or not. There is no standard approach to anesthesia in premature infants with the decision to use a specific drug or drugs often based on the clinical impression of the anesthesiologist, an "expert opinion", or preliminary studies with the overwhelming majority of anesthetic drugs used in neonates not approved by the FDA. This is clearly an issue when the highest risk and most complex preterm infants need to be anesthetized for a surgical procedure.

How does this Apply to Anesthesiology?
======================================

Anesthesiologists caring for neonates have to understand that most marketed drugs approved by the FDA are labeled only for use in adult patients. Withholding anesthesia from neonates who need surgery is impossible, so the use of one or more agents is often based on routine practice, experience, availability, and limited data. Between 1998 and 2003, the FDA issued written requests for the study of 242 drugs, with 53 studies actually conducted; 12 (23%) were evaluated for safety only; 23 (43%) for safety and efficacy and 18 (34%) for pharmacokinetics and/or pharmacodynamics. However, only nine of these studies involved drugs used for anesthesia, pain and sedation and only two of these studies were published ([@bib15]). Most importantly, only four of these studies involved infants less than one year of age. Negative results are equally important as positive data since they may demonstrate safety concerns or lack of effectiveness, especially in younger age groups. This will also serve to notify other investigators that the study of a specific drug in a certain age range has been completed. Neonates are a vulnerable population and exposure to drugs should be limited as evidence for safety or toxicity is still lacking. In fact, extrapolation from adult data was proposed by the FDA in 1994; Dunne *et al*. ([@bib16]) have shown that 61% of drugs studied using this approach received an indication in children when extrapolation was used. Under certain circumstances, this approach could potentially increase the number of drug approvals for pediatric use without requiring additional pediatric studies. It is clear that registering all clinical studies on clinicaltrials.gov should be mandatory and publishing all relevant data should be done irrespective of outcome ([@bib17]).

Specific Anesthetic Agents
==========================

In anesthesiology, different classes of drugs and different combinations are used to provide amnesia, relaxation, and a pain-free experience. From 2003 until the present, BPCA and PREA have facilitated the study of anesthetic-related drugs including propofol, ketamine, inhalational anesthetics (desflurane, sevoflurane, isoflurane), opioids (fentanyl, morphine, oxycodone, remifentanil), benzodiazepines (midazolam, lorazepam), muscle relaxants (rocuronium), α-2 adrenoreceptor agonists (dexmedetomidine), and local anesthetics (lidocaine) in children ([@bib18]). These efforts have included safety, efficacy, pharmacokinetic, and pharmacodynamic studies leading to updated labeling and safety information. For instance, there were a higher percentage of deaths reported with patients who received propofol compared with controls and more seizures occurred in children who received sevoflurane during surgery ([@bib18]). However, only three of these studies involved neonates (e.g., rocuronium, remifentanil, sevoflurane) and none included premature infants, especially those born at 23--29 wk of gestation who are at the highest risk of death or neurodevelopmental impairment (**[Table 2](#tbl2){ref-type="table"}**) ([@bib2],[@bib9],[@bib18],[@bib19]).

Among the inhalational anesthetics, data mentioned on the drug labels indicate that it appears to be safe and effective to use sevoflurane in neonates as young as 9 d of age and desflurane in infants as young as 2 y of age. However, recent data demonstrate a neurotoxic effect on the fetus and newborn in animals who have received some of these inhaled agents ([@bib20]). Propofol can be administered for induction down to 3 y of age and for maintenance down to 2 mo of age, but significant concerns exist with using this agent in neonates ([@bib2],[@bib19]). Midazolam is a benzodiazepine that is routinely administered to neonates in the NICU, but does require modification of dosing in children with congenital heart disease and pulmonary hypertension ([@bib21]). A recent Cochrane review found insufficient data to justify the routine use of midazolam in neonates and raised concerns about adverse neurologic outcomes ([@bib21]). Based on the new pediatric drug-labeling database, the only muscle relaxant that has been studied in newborn infants is rocuronium, a nondepolarizing muscle relaxant ([@bib2],[@bib9]) Among the opioids, the efficacy and safety of remifentanil as an analgesic agent for use in the maintenance of general anesthesia has been examined in 21 premature infants at 29--32 wk of gestation ([@bib22],[@bib23]). However, definitive safety of fentanyl has not been established in children younger than 16 y of age which is concerning since this agent is routinely used for sedation and pain control in extremely premature infants in the NICU as well as routinely during surgery ([@bib2]). A 2005 study showed an increased incidence of side effects including need for respiratory support and delay in achieving full enteral feedings with continuous fentanyl infusions compared to open-label boluses in very preterm infants receiving mechanical ventilation ([@bib24]). Morphine, is a commonly used analgesic in preterm infants in NICU. While the use of this agent has been found to be associated with an increased risk of intraventricular hemorrhage and prolonged electrocortical depression on electroencephalogram, longer-term studies have not demonstrated any changes in the general function of children at 8--9 y and potential improvement in their executive functioning ([@bib25],[@bib26],[@bib27]). Dexmedetomidine is a selective α-2 adrenoreceptor agonist that produces sedation and has antinociceptive properties. A phase II/III multicenter study demonstrated the safety and efficacy of dexmedetomidine in sedating preterm and full-term neonates without significant adverse events ([@bib28]). Safety and effectiveness of local anesthetics such as lidocaine (routinely used subcutaneously for invasive procedures or surgeries) has not been established in children less than 12 y of age ([@bib18]). These studies are particularly important since they provide evidence that pediatric dosing should not be determined by simply applying weight-based calculations to the adult dose. Drug clearance is highly variable in the pediatric population and is not readily predictable on the basis of adult information.

Anesthesiology Initiatives
==========================

In addition to the relative lack of safety data, recent *in vitro* and *in vivo* studies have shown that the use of a variety of anesthetic agents in children less than three years of age (especially neonates and young infants) may cause neurotoxicity and possible long-term adverse neurodevelopmental outcomes as described in detail by Ramsay and Rappaport as well as Sun and associates ([@bib29],[@bib30]). In response to these concerns, the FDA\'s Anesthetic and Life Support Drugs Advisory Committee met in March 2007 and again in March 2011 concluding that there were insufficient data to warrant a change of practice. Subsequently, FDA entered into a public-private partnership with the International Anesthesia Research Society (IARS) called SmartTots (Strategies for Mitigation of Anesthesia-Related Neurotoxicity in Tots) to mobilize the scientific community, stimulate dialogue among thought leaders in the anesthesia community, and work to generate funding for the necessary research studies. Two major prospective studies are ongoing in children: (i) The Pediatric Anesthesia Neurodevelopmental Assessment Study (PANDA) are comparing siblings less than 3 y of age exposed to general anesthesia to those nonexposed; (ii) The GAS study is a multisite randomized controlled trial comparing neurodevelopmental outcomes in infants receiving general anesthesia compared to spinal and other regional anesthetics to control for the stress response to surgery ([@bib29]). A recent retrospective cohort analysis of 12,111 preterm infants from the NICHD neonatal research network database demonstrated an independent association between infants undergoing a major surgical procedure and an increased risk of death or neurodevelopment impairment compared to infants having minor surgical procedures or no surgery ([@bib31]). While the authors speculate that the effects of general anesthesia may have contributed to the abnormal outcomes, specific data on the types of anesthetic agents used (or combination of agents) was not available making it extremely difficult to establish a definitive association. While results of the GAS and PANDA studies are pending, Neonatologists, Pediatricians, Surgeons, and Anesthesiologists should be aware of potential neurotoxicity of anesthetics and sedatives ([@bib32]). The use of spinal and regional anesthetics is definitely increasing for a variety of procedures where it can be safely employed.

Challenges to Conducting Clinical Studies in Neonates
=====================================================

There are several unique limitations to conducting studies of anesthetic agents in neonates undergoing surgery since the use of anesthesia and analgesia is mandatory, the use of a placebo cannot be justified, and there are few comparative effectiveness studies demonstrating the benefit of a wide range of approaches (single or multiple systemic and/or inhaled agents) ([@bib33]). In addition to difficulty in study design and choosing relevant outcome measures, obtaining parental consent for a research study of one or more anesthetic agents in a critically ill premature infant requiring a major surgical procedure may be challenging. The Anesthesiologist must address the risks and benefits as well as the degree of parental distress when surgery is required in a premature infant ([@bib34]).

The evaluation of drug safety and efficacy requires a comprehensive assessment of the pharmacodynamics and pharmacokinetics of the drug. However, the continued maturation of different organ systems (especially the brain) as well as the developmental changes in receptor number and affinity throughout infancy can greatly influence the susceptibility of the premature infant to the effects of single or multiple anesthetic agents. There are multiple important age-related trends that must be analyzed including: (i) behavioral and autonomic responses to noxious stimuli, (ii) hepatic enzyme systems important for drug metabolism, (iii) Renal clearance of drugs and their metabolites, (iv) age-related differences in drug uptake and distribution, (v) pharmacodynamic responses to medications, (vi) respiratory response to opioids, (vii) genetic polymorphisms in opioid receptors (OPMR1), transporters, and other enzyme systems that may significantly influence the response to different anesthetic agents, (viii) sensitivity of neurons to apoptotic or necrotic cell death following a variety of physiologic events or pharmacologic exposures, (ix) hemodynamic responses to general anesthesia, spinal anesthesia, and epidural anesthesia, (x) hormonal and metabolic responses to surgery and illness, and (xi) the strong possibility of drug--drug interactions since multiple agents are routinely administered in various combinations to the smallest and most critically ill preterm infants ([@bib35],[@bib36],[@bib37]).

Conclusion
==========

Our knowledge of the maturation of specific metabolic pathways is increasing, yet new and existing drugs are being administered to neonates each year without adequate safety profiles being identified and older drugs continue to be used in the absence of definitive safety and efficacy data. A process to address these deficiencies remains an urgent public health need. National legislation and funding opportunities are available to encourage clinical and basic research studying safety, potential toxicity, and effectiveness of drugs used routinely for anesthesia and analgesia in preterm and infants.

Recommendations for best practices for Pediatric Anesthesiologists or preferred clinical pathways for specific surgeries limiting the doses and exposure of single or multiple drugs is needed. In the interim, clinicians are advised to continue to tailor the care of neonates based on the patient\'s condition, to attempt to limit the exposure to multiple agents if possible, to consider alternative therapeutic approaches (e.g., spinal, local anesthetics) if viable, and to remain vigilant as new information is developed.
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